North America Hereditary Cancer Testing Market to 2027 - Regional Analysis and Forecasts by Diagnosis Type (Biopsy, Imaging); Technology (Sequencing, PCR, Microarray); End User (Hospital, Clinics, Diagnostic Centers), and Country
Publication Month: Oct 2019
Report Code: TIPRE00006806 No. of Pages: 132 Category: Biotechnology Status: Published
The North America hereditary cancer testing market is expected to reach US$ 3,247.37 Mn in 2027 from US$ 1,255.79 Mn in 2018. The market is estimated to grow with a CAGR of 11.6% from 2019-2027.
The growth of the market is driven by factors such as, growing awareness about hereditary cancer and favorable reimbursement scenario. However, market growth is likely to slow down due to the gender gap in cancer genetic testing in the region.
Personalized medicines is a comparatively new idea that allows doctors to select medication based on a patient's hereditary profile; it is a developing area in the healthcare sector. The method not only reduces adverse side effects but also manages to produce strong results in a short period. For instance, mutations in BRCA1 and BRCA2 lead to breast cancer. However, identifying the type of variation in the breast cancer patient provides crucial information for the kind of treatment. Hence, personalized medicines allow right treatment at the right time, which reduces the mortality rate. On the back of these advantages, the personalized medicine approach is likely to create many opportunities for the hereditary cancer testing market players.
The US is expected to lead the market in the North America region to the rapidly increasing expenditure of research and development by biopharmaceutical companies. Moreover, various biopharmaceutical companies are focusing on the development of new cancer panel and direct to consumer test. Therefore, considering the factors mentioned above, growth of the market in the US is likely to contribute the most significant share in the North America region during the forecast period.
Exhibit: Mexico Hereditary cancer testing Market Revenue and Forecasts to 2027 (US$ Mn)
NORTH AMERICA HEREDITARY CANCER TESTING – MARKET SEGMENTATION
BY DIAGNOSIS TYPE
- Biopsy
- Blood Sample
- Cheek Swab Sample
- Imaging
BY TECHNOLOGY
- Sequencing
- PCR
- Microarray
BY END USER
- Diagnostic Centers
- Hospital
- Clinics
Company Profiles
- Biosero Inc.
- Hologic Inc.
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Myriad Genetics, Inc.
- Cancer Genetics Inc.
- Invitae Corporation
- Myogenes
- Strand Life Sciences Pvt. Ltd.
- Pathway Genomics Corporation
- CENTOGENE AG
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
2. North America Hereditary Cancer Testing Market – Key Takeaways
3. North America Hereditary Cancer Testing Market – Market Landscape
3.1 Overview
3.2 Market Segmentation
3.2.1 Global Hereditary Cancer Testing Market – By Diagnosis Type
3.2.2 Global Hereditary Cancer Testing Market – By Technology
3.2.3 Global Hereditary Cancer Testing Market – By End User
3.2.4 North America Hereditary Cancer Testing Market – By Country
3.3 PEST Analysis
4. North America Hereditary Cancer Testing Market - Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Favourable Reimbursement Scenario
4.1.2 Growing Awareness About Hereditary Cancer
4.2 Key Market Restraints
4.2.1 Gender Gap In Cancer Genetic Test
4.3 Key Market Opportunities
4.3.1 Whole Genome Sequencing (WGS) for Cancer
4.4 Future Trends
4.4.1 Demand For Personalized Medicines
4.5 Impact Analysis
5. Hereditary Cancer Testing Market – North America Analysis
5.1 North America Hereditary Cancer Testing Market Revenue Forecasts And Analysis
5.2 Performance of Key Players
6. North America Hereditary Cancer Testing Market Analysis – By Diagnosis Type
6.1 Overview
6.2 North America Hereditary Cancer Testing Market by Diagnosis Type, 2018 & 2027 (%)
6.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Diagnosis Type (US$ Mn)
6.4 Biopsy Market
6.4.1 Overview
6.4.2 North America Biopsy Market Revenue and Forecasts to 2027 (US$ Mn)
6.4.3 Blood Sample Market
6.4.3.1 Overview
6.4.3.2 North America Blood Sample Market Revenue and Forecasts to 2027 (US$ Mn)
6.4.4 Cheek Swab Sample Market
6.4.4.1 Overview
6.4.4.2 North America Cheek Swab Sample Market Revenue and Forecasts to 2027 (US$ Mn)
6.5 Imaging Market
6.5.1 Overview
6.5.2 North America Imaging Market Revenue and Forecasts to 2027 (US$ Mn)
7. North America Hereditary Cancer Testing Market Analysis – By Technology
7.1 Overview
7.2 North America Hereditary Cancer Testing Market by Technology, 2018 & 2027 (%)
7.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Technology (US$ Mn)
7.4 Sequencing Market
7.4.1 Overview
7.4.2 North America Sequencing Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Polymerase Chain Reaction (PCR) Market
7.5.1 Overview
7.5.2 North America Polymerase Chain Reaction (PCR) Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Microarray Market
7.6.1 Overview
7.6.2 North America Microarray Market Revenue and Forecasts to 2027 (US$ Mn)
8. North America Hereditary Cancer Testing Market Analysis – By End User
8.1 Overview
8.2 North America Hereditary Cancer Testing Market by End User, 2018 & 2027 (%)
8.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By End User (US$ Mn)
8.4 Diagnostic Centers Market
8.4.1 Overview
8.4.2 North America Diagnostic Centers Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Hospitals Market
8.5.1 Overview
8.5.2 North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Clinics Market
8.6.1 Overview
8.6.2 North America Clinics Market Revenue and Forecasts to 2027 (US$ Mn)
9. North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027
9.1.1 Overview
9.1.2 North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.3 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.3.1 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.4 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.5 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.6 North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027, By Country (%)
9.1.7 US Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.7.1 US Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.7.2 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.7.2.1 US Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.7.3 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.7.4 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.8 Canada Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.8.1 Canada Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.8.2 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.8.2.1 Canada Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.8.3 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.8.4 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.9 Mexico Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.9.1 Mexico Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.9.2 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.9.2.1 Mexico Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.9.3 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.9.4 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
10. Hereditary Cancer Testing Market – Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Hereditary Cancer Testing Market, 2016-2019
10.3 Organic Growth Strategies
10.3.1 Overview
10.3.2 Product Launch
10.3.3 Product Approval
10.3.4 Others
10.4 Inorganic Growth Strategies
10.4.1 Overview
10.4.2 Partnership
10.4.3 Agreement & Collaboration
10.4.4 Acquisition
11. Hereditary Cancer Testing Market–Key Company Profiles
11.1 Hologic Inc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Financial Overview
11.1.4 Product Portfolio
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Koninklijke Philips N.V.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Financial Overview
11.2.4 Product Portfolio
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Quest Diagnostics Incorporated
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Financial Overview
11.3.4 Product Portfolio
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Myriad Genetics, Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Financial Overview
11.4.4 Product Portfolio
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Cancer Genetics Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Financial Overview
11.5.4 Product Portfolio
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Invitae Corporation
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Financial Overview
11.6.4 Product Portfolio
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Myogenes
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Financial Overview
11.7.4 Product Portfolio
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Strand Life Sciences Pvt. Ltd.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Financial Overview
11.8.4 Product Portfolio
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Pathway Genomics Corporation
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Financial Overview
11.9.4 Product Portfolio
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 CENTOGENE AG
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Financial Overview
11.10.4 Product Portfolio
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary Of Terms
12.3 Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
LIST OF TABLES
Table 1. R&D Investments by Major Pharmaceutical Companies
Table 2. R&D Investments by PhRMA member companies,2016
Table 3. Number of Registered Studies for Clinical Trials
Table 4. Consolidation Across the CRO Industry
Table 5. North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Diagnosis Type (US$ Mn)
Table 6. North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Technology (US$ Mn)
Table 7. North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By End User (US$ Mn)
Table 8. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 9. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 10. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 11. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 12. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 13. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 14. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 15. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 16. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 17. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 18. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 19. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 20. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 21. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 22. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 23. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 24. Recent Product Launch in the Hereditary Cancer Testing Market
Table 25. Recent Product Approval in the Hereditary Cancer Testing Market
Table 26. Recent Other Growth Strategies in the Hereditary Cancer Testing Market
Table 27. Partnerships in the Hereditary Cancer Testing Market
Table 28. Agreement & Collaboration in the Hereditary Cancer Testing Market
Table 29. Acquisitions in the Hereditary Cancer Testing Market
Table 30. Glossary of Terms, Hereditary Cancer Testing Management Market
LIST OF FIGURES
Figure 1. US Hereditary Cancer Testing Market, Revenue (US$ Mn), By Country 2018 & 2027
Figure 2. North America Hereditary Cancer Testing Market By Diagnosis Type , Market Share (%), 2018
Figure 3. North America Hereditary Cancer Testing Market By Technology, Market Share (%), 2018
Figure 4. North America Hereditary Cancer Testing Market By End User, Market Share (%), 2018
Figure 5. Hereditary Cancer Testing Market Segmentation
Figure 6. North America PEST Analysis
Figure 7. Hereditary Cancer Testing Market Impact Analysis of Drivers & Restraints
Figure 8. North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 9. Prominent Players in the Hereditary Cancer Testing Market
Figure 10. North America Hereditary Cancer Testing Management Market, By Diagnosis Type 2018 & 2027 (%)
Figure 11. North America Biopsy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. North America Blood Sample Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. North America Cheek Swab Sample Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. North America Imaging Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. North America Hereditary Cancer Testing Market, By Technology 2018 & 2027 (%)
Figure 16. North America Sequencing Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. North America Polymerase Chain Reaction (PCR) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. North America Microarray Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. North America Hereditary Cancer Testing Market, By End User 2018 & 2027 (%)
Figure 20. North America Diagnostic Centers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. North America Clinics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. North America Hereditary Cancer Testing Market Revenue, by Country, 2018 (US$ Mn)
Figure 24. North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027, By Country (%)
Figure 26. US Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Canada Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 28. Mexico Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. Growth Strategies in the Hereditary Cancer Testing Market, 2016-2019
Figure 30. Organic Growth Strategies in the Hereditary Cancer Testing Market, 2016-2019
Figure 31. Inorganic Growth Strategies in the Hereditary Cancer Testing Market, 2016-2019
The List of Companies
- Biosero Inc.
- Hologic Inc.
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Myriad Genetics, Inc.
- Cancer Genetics Inc.
- Invitae Corporation
- Myogenes
- Strand Life Sciences Pvt. Ltd.
- Pathway Genomics Corporation
- CENTOGENE AG
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America hereditary cancer testing market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America hereditary cancer testing market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth the North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.